Medicane to supply cannabis flowers to Germany through Cantourage

A Medicane – MHI Medicinal Cultivation SA, which has its medical cannabis production unit in Campo Maior, Alentejo, has entered into a strategic partnership with Cantourage, to supply German pharmacies with a new brand of medical-grade dried cannabis flowers called Relecan. Speaking to Cannareporter, Vera Broder, CEO of MHI, said that the company is preparing the ACM application – Marketing Authorization – to submit to Infarmed, so that it can also supply the Portuguese market. 

The product Relecan, of Portuguese origin, can be prescribed to patients suffering from chronic pain, convulsions and various other diseases, and is now available in pharmacies throughout Germany. MHI has been operating in Portugal since 2019 and was designated a “Project of National Interest” (PIN) by the Portuguese government in March 2021 in recognition of its key role in providing medical cannabis products to patients in Europe.

Cantourage will manufacture Relecan, a new brand of dried medicinal cannabis flowers, produced in Portugal by Medicane, which will be available for sale in Germany, by prescription. The German company mentioned, in Press release, that “the product quality of Relecan dried flowers is unique thanks to Canna-Wave radio frequency technology, which eliminates the need for commonly used chemical pesticides”. MHI grows the flowers in its greenhouses in Alto Alentejo, near Campo Maior and the process used by Cantourage reduces the microbiological load of the product, which avoids the ionizing radiation used by most other cannabis companies, in the same technological line as MediCane in cultivation.

Relecan flowers are grown by expert agronomists at MHI, based on cannabis-growing techniques developed over more than a decade by the experts at MediCane in Israel. The country is one of the most advanced in medical cannabis research, with Israeli scientists conducting research into the medical applications of cannabis for more than five decades.

Philip Schetter, Co-CEO of Cantourage, said: “The new partnership with MHI Cultivo Medicinal and the launch of Relecan in Germany represents a significant milestone in the advancement of medical cannabis in Europe. Record imports of dried flower products to Germany last year show the real demand for this segment. Cantourage is motivated to meet this growing need with a high quality product and in partnership with such an innovative, technologically and environmentally conscious grower.”

Vera Broder, CEO of MHI Cultivo Medicinal, said: “German patients deserve high quality medical cannabis, grown in Europe and environmentally sustainable, and we are pleased to introduce our products to German pharmacies together with Cantourage.”

In a press release, Cantourage also stressed that the new product, Relecan, is “particularly of high quality and distinguished for three reasons: the climatic conditions in Portugal are considered the most favorable in Europe in terms of temperature and humidity levels. , throughout the four seasons; flowers are protected during cultivation, using radiofrequency Canna-Wave technology, which has been integrated into cannabis pest control practices; Cantourage guarantees that it treats the product with its unique microbiological reduction process, which allows it to minimize the microbiological load without the use of irradiation, improving product quality without the need for additional regulatory steps, which further accelerates the production schedule and delivery".

Cantourage's agreement with MHI Cultivo Medicinal provides for the company's accession to Cantourage's quick access platform. The platform was launched in June 2021 to enable medical cannabis growers around the world to enter these markets quickly and compliantly. Cantourage has signed contracts with 15 companies worldwide and MHI is the third partner to successfully launch its products, which have been available in German pharmacies since last week.